The UK’s drug regulator, the MHRA, released its strategic approach to regulating AI in medicinal products on 30 April. Much of the guidance focuses on how the MHRA plans to use AI during the regulatory assessment process for drugs, and on AI as a medical device.
The organization also said that machine learning and AI could be used to enhance its understanding of real-world data (RWD), although at this stage there were “significant uncertainties” around the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?